Develops drugs for pancreatic and colorectal cancers.
Jun 2026Revenue $3.26M/yrExpenses $5.90M/yr
No trendCash runway ≈ 2.8 years from Jun 2026
Figures by year
When will Xenetic Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $3.26M and expenses $5.90M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.98M | $5.81M | −$2.83M |
| Dec 2024 | $2.50M | $6.70M | −$4.20M |
| Dec 2023 | $2.54M | $7.06M | −$4.52M |
| Dec 2022 | $1.71M | $8.42M | −$6.72M |
| Dec 2021 | $1.16M | $6.91M | −$5.75M |
| Dec 2020 | $437K | $14.4M | −$13.9M |
| Dec 2019 | $17.1K | $12.9M | −$12.9M |
| Dec 2018 | $0.00 | $7.28M | −$7.28M |
| Dec 2017 | $7.58M | $11.2M | −$3.57M |
| Dec 2016 | $3.00M | $50.4M | −$47.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.